Table 2.
Use of cytogenetic testing by country and cohort
| All | France | Germany | Italy | UK | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Early (N = 592) | Recent (N = 244) | Early (N = 176) | Recent (N = 93) | Early (N = 156) | Recent (N = 57) | Early (N = 95) | Recent (N = 41) | Early (N = 165) | Recent (N = 53) | |
| Cytogenetic testing done, n (%) | 125 (21) a , a | 85 (35) a , a | 69 (39) | 44 (47) | 15 (10) | 10 (18) | 19 (20) | 12 (29) | 22 (13) a , a | 19 (36) a , a |
| High risk | 32 (5) a , a | 19 (8) a , a | 17 (10) | 10 (11) | 4 (3) | 2 (4) | 4 (4) | 2 (5) | 7 (4) a , a | 5 (9) a , a |
| Standard risk | 93 (16) | 66 (27) | 52 (30) | 34 (37) | 11 (7) | 8 (14) | 15 (16) | 10 (24) | 15 (9) | 14 (26) |
| Unknown risk | 467 (79) | 159 (65) | 107 (61) | 49 (53) | 141 (90) | 47 (82) | 76 (80) | 29 (71) | 143 (87) | 34 (64) |
a
Denoting significant differences between early and recent cohort (P < .05). Abbreviations: CCI, Charlson comorbidity index; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, international staging system; UK, United Kingdom.